Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study

Frola, Claudia; Arístegui, Inés; Figueroa, María Inés; Radusky, Pablo David; Cardozo, Nadir; Zalazar, Virginia; César, Carina; Patterson, Patricia; Fink, Valeria; Gun, Ana; Cahn, Pedro; Sued, Omar

doi:10.1371/journal.pone.0279996

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TransCITAR is a prospective cohort study of transgender individuals living in the metropolitan area of Buenos Aires, Argentina. The details of TransCITAR have been described elsewhere ( 14 ). Study procedures were approved and monitored by Fundacion Huesped’s Institutional Review Board (IRB00002014 # FH-41).…”

Section: Methodsmentioning

confidence: 99%

“…This information is urgently needed to develop and implement interventions to decrease the current smoking rates in LMICs. Second, this study builds upon an established history of research with the transgender community (34)(35)(36)(37)(38)(39). Third, this work is grounded in principles of community-based participatory research (CPBR).…”

Section: Strengths and Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and correlates of current cigarette smoking among transgender women in Argentina

Cartujano-Barrera,

Mejia,

Radusky

et al. 2023

Front. Public Health

Self Cite

View full text Add to dashboard Cite

ObjectiveTo assess the prevalence of current cigarette smoking among transgender women in Argentina, and to examine the unique associations of current cigarette smoking with demographic and psychosocial factors.MethodsThis study is a secondary data analysis of the TransCITAR – a prospective cohort study of transgender individuals living in Buenos Aires, Argentina – baseline data. The baseline survey collected information on sociodemographic characteristics, perceived health status, depressive symptoms, suicide attempts, current cigarette smoking, alcohol use disorder, and substance use. Participants were also asked about lifetime experiences of physical and sexual violence perpetrated by partners, clients and/or the police, and experiences of gender identity stigma in the past year from healthcare workers and the police. Lastly, participants were asked if they had ever been arrested. Fisher’s exact test was used to compare proportions in categorical variables and student t-test was used for continuous variables. Significant associations with current cigarette smoking were tested in a logistic regression model adjusted for all significant associations.ResultsA total of 41.7% of participants (n = 393) reported current cigarette smoking. Compared to their non-smoking counterparts, participants who reported current cigarette smoking (1) had completed less education, (2) were more likely to be born in Argentina, (3) more likely to had migrated to Buenos Aires from other parts of the country, (4) more likely to report a history of sex work, (5) more likely to perceive their health as excellent, (6) more likely to screen positive for hazardous alcohol drinking, (7) more likely to report any substance and cocaine use in the past year, (8) more likely to experience gender identity stigma from the police in the past year, and (9) more likely to being arrested in their lifetime (all p’s < 0.05). After controlling for all significant associations, education level of less than high school (AOR = 1.79, 95% CI 1.02–2.12), hazardous drinking (AOR = 2.65, 95% CI 1.30–5.37), and any substance use in the last year (AOR = 2.14, 95% CI 1.16–3.94) were positively and independently associated with current cigarette smoking.ConclusionAmong transgender women in Argentina, current cigarette smoking was more than double the rate for cisgender women. Current cigarette smoking was associated with education, hazardous drinking, and any drug use. These results will inform future smoking cessation interventions among transgender women in Argentina.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Strengths and Limitationsmentioning

confidence: 99%

Prevalence and correlates of current cigarette smoking among transgender women in Argentina

Cartujano-Barrera,

Mejia,

Radusky

et al. 2023

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is paucity of literature that describes ART adherence among transgender women. 14 To facilitate treatment continuity and retention in care for the transgender women on ART, the researchers found it essential to explore and describe determinants of ART adherence among transgender women living with HIV in Buffalo City, South Africa, exploring all the steps across the prevention and treatment cascade in this community.…”

Section: Introductionmentioning

confidence: 99%

Determinants of antiretroviral therapy adherence among transgender women in South Africa

van der Merwe,

Moyo,

Mavhandu-Mudzusi

2024

South African Family Practice

View full text Add to dashboard Cite

Background: Transgender women bear a huge burden of human immunodeficiency virus (HIV) in South Africa. However, they are not fully engaged in healthcare across the HIV continuum of care. In addition, transgender women face multiple facets of stigma and discrimination as well as socio-economic inequalities, which all have a negative impact on antiretroviral therapy (ART) adherence.Objective: The study aimed at exploring and describing the experiences of ART adherence of transgender women living with HIV in the Buffalo City Metro Municipality.Methods: The study employed an interpretative phenomenological analysis (IPA) design. Twelve participants were enrolled using a snowballing sampling technique. Data were collected using semi-structured interviews and analysed using an IPA framework.Results: While exploring determinants to ART adherence among transgender women living with HIV in Buffalo City Metro, two superordinate themes emerged: enablers to ART adherence and psychosocial factors promoting adherence. The study found that factors such as differentiated ART service delivery, ARV medicines-related factors, motivators for taking treatment and support systems facilitated ART adherence.Conclusion: Emerging from this study is the need to scale up differentiated, person-centred ART service deliveries that will enhance access and adherence to treatment for transgender women.Contribution: This study provides unique insights on factors enhancing ART adherence among transgender women. There is a paucity of literature on access to HIV care services for key and vulnerable populations, and these findings will be shared in the country and in the region.

show abstract

Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV

Senneker

2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

Transgender persons face a greater burden of HIV compared to cisgender counterparts. Concerns around drug–drug interactions (DDIs) have been cited as reasons for lower engagement in HIV care and lower pre‐exposure prophylaxis (PrEP) uptake among transgender populations. It is therefore imperative for hormone therapy, PrEP and antiretroviral therapy providers to understand the DDI potential between these therapies.Studies of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) PrEP with feminizing hormone therapies (FHTs) show reduced plasma tenofovir concentrations, but intracellular concentrations of tenofovir‐diphosphate are not reduced. Efficacy of PrEP is expected to be maintained despite this interaction. Masculinizing hormone therapies have no effect on tenofovir concentrations but may increase FTC to a nonclinically relevant extent. No interactions between FHT and cabotegravir or tenofovir alafenamide have been demonstrated. Administration of TDF/FTC PrEP has no effect on hormone levels in transmen or transwomen. PrEP is expected to be effective and safe in transpersons and should be provided to high‐risk individuals regardless of gender affirming hormone use.Enzyme inducing/inhibiting antiretroviral therapy may decrease or increase, respectively, the concentrations of FHT and masculinizing hormone therapy. Unboosted integrase inhibitors or enzyme neutral non‐nucleoside reverse transcriptase inhibitors are not expected to affect and are not affected by gender affirming hormones and can be considered in transmen and transwomen. Overlapping toxicities including weight gain, dyslipidaemia, cardiovascular disease and bone density effects should be considered, and antiretroviral modifications can be made to minimize toxicities. Interactions between supportive care medications should be assessed to avoid chelation interactions and hyperkalaemia.

show abstract

Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study

Cited by 4 publications

References 35 publications

Prevalence and correlates of current cigarette smoking among transgender women in Argentina

Prevalence and correlates of current cigarette smoking among transgender women in Argentina

Determinants of antiretroviral therapy adherence among transgender women in South Africa

Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV

Contact Info

Product

Resources

About